Unknown

Dataset Information

0

Fulvestrant for hormone-sensitive metastatic breast cancer.

ABSTRACT:

SUBMITTER: Lee CI 

PROVIDER: S-EPMC6464820 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience.
| S-EPMC8391338 | biostudies-literature
Unknown Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.
| S-EPMC6865233 | biostudies-literature
Unknown Combination anastrozole and fulvestrant in metastatic breast cancer.
| S-EPMC3951300 | biostudies-literature
Unknown Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
| S-EPMC4562797 | biostudies-literature
Unknown Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.
| S-EPMC7462248 | biostudies-literature
Unknown Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.
| S-EPMC2660860 | biostudies-literature
Unknown Metastatic hormone-sensitive prostate cancer: How should it be treated?
| S-EPMC7918528 | biostudies-literature
Unknown WHO SHOULD RECEIVE RADIOTHERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER?
| S-EPMC8693553 | biostudies-literature
Unknown Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer.
| S-EPMC9329443 | biostudies-literature
Unknown Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
| S-EPMC6407749 | biostudies-literature